Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.69 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546411 | 1.00 | HRH3 (0.69) | HRH3PRMT6ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL29447423 | 0.98 | HRH3 (0.67) | HRH3PRMT6ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL12854 | 0.98 | HRH3 (0.67) | HRH3PRMT6ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL24495602 | 0.90 | HRH3 (0.57) | HRH3PRMT6ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL26010164 | 0.88 | HRH3 (0.69) | HRH3PRMT6ALDH1A1KDM4EMAPT | |
| SCHEMBL28849168 | 0.85 | CXCR4 (0.64) | HRH3ALDH1A1TDP1KDM4EMAPT | |
| SCHEMBL20663301 | 0.85 | NCF1 (0.59) | HRH3ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL19206094 | 0.85 | ALDH1A1 (0.61) | HRH3PRMT6ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL29863040 | 0.85 | CXCR4 (0.64) | HRH3ALDH1A1TDP1KDM4EMAPT | |
| SCHEMBL2262681 | 0.85 | ALDH1A1 (0.57) | HRH3ALDH1A1KDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3800187-A1 | ORGANIC IMAGE SENSOR COMPRISING SPECIFIC NAPHTHALENEDIIMIDE COMPOUND | Sony Corporation (JP) | 2021-04-07 | — | — | EP | disclosed |
| US-20210005827-A1 | N AND P ACTIVE MATERIALS FOR ORGANIC PHOTOELECTRIC CONVERSION LAYERS IN ORGANIC PHOTODIODES | SONY CORPORATION (JP) | 2021-01-07 | — | — | US | disclosed |
| EP-3461828-B1 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10790454-B2 | N and P active materials for organic photoelectric conversion layers in organic photodiodes | SONY CORPORATION (JP) | 2020-09-29 | — | — | US | disclosed |
| US-10464935-B2 | Specific N and P active materials for organic photoelectric conversion layers in organic photodiodes | SONY CORPORATION (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3461828-A2 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES, INC. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10233157-B2 | SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180215719-A9 | SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215719-A9 | SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006003440-A1 | 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215719-A9 | SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER | SIK1, SIK2, SGK1 | HRH3 1246/4885PRMT6 1761/4885ALDH1A1 4501/4885 |
| US-10790454-B2 | N and P active materials for organic photoelectric conversion layers in organic photodiodes | L1CAM, PNN, JUP | HRH3 4742/4885PRMT6 2578/4885ALDH1A1 2724/4885 |
| US-10233157-B2 | SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder | SIK1, SIK2, SGK1 | HRH3 1246/4885PRMT6 1761/4885ALDH1A1 4501/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | HRH3 92/4885PRMT6 1576/4885ALDH1A1 1154/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | HRH3 4646/4885PRMT6 1491/4885ALDH1A1 1157/4885 |
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | HRH3 4348/4885PRMT6 1600/4885ALDH1A1 1875/4885 |
| US-10464935-B2 | Specific N and P active materials for organic photoelectric conversion layers in organic photodiodes | L1CAM, JUP, DSP | HRH3 4288/4885PRMT6 2967/4885ALDH1A1 3045/4885 |
| US-20210005827-A1 | N AND P ACTIVE MATERIALS FOR ORGANIC PHOTOELECTRIC CONVERSION LAYERS IN ORGANIC PHOTODIODES | L1CAM, PNN, JUP | HRH3 4742/4885PRMT6 2578/4885ALDH1A1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.